# Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

> **NCT01789827** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 5 (actual)

## Conditions studied

- Stage IV Skin Melanoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Radionuclide Imaging
- **BIOLOGICAL:** Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2

## Key facts

- **NCT ID:** NCT01789827
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2018-06-27
- **Final completion:** 2018-06-27
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01789827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01789827, "Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01789827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*